Muscle-Related Adverse Events Associated With PCSK9 Inhibitors in a Veteran Population.

Background: Statins and PCSK9 inhibitors (PCSK9i) are used to lower low-density lipoprotein cholesterol and reduce cardiovascular events, yet some patients are unable to tolerate statin therapy due to muscle-related adverse events (AEs). The effect of PCSK9i on muscle-related AEs is not well studied, and available data show inconsistent incidence rates.

Methods: The primary study outcome was to determine the percentage of patients who developed muscle-related PCSK9i AEs.